SENECA is a new unique cell therapy clinical trial that may be of interest to patients who are cancer survivors with left ventricular dysfunction secondary to anthracycline-induced cardiomyopathy (AIC).
The trial, called SENECA (StEm cell iNjEction in CAncer survivors), is being conducted by the Cardiovascular Cell Therapy Research Network (CCTRN), and funded by the National Heart, Lung, and Blood Institute). It is designed to assess the safety, feasibility, and effect of delivering allogeneic mesenchymal stem cells (allo-MSCs) via
transendocardial injection in cancer survivors diagnosed with AIC. In this phase I study, we hypothesize that these cells will be well-tolerated, and when compared with placebo, will demonstrate trends toward scar reduction and improved cardiac performance, functional capacity, and quality of life.